Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma
IntroductionAlthough PD-1/L1 mAb has demonstrated clinical benefits in certain cancer types, low response rate and resistance remain the main challenges for the application of these immune checkpoint inhibitors (ICIs). 4-1BB is a co-stimulator molecule expressed in T cells, which could enhance T cel...
Main Authors: | Yichen Wang, Xuyao Zhang, Caili Xu, Yanyang Nan, Jiajun Fan, Xian Zeng, Byoung S. Kwon, Dianwen Ju |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1004475/full |
Similar Items
-
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
by: Christina Claus, et al.
Published: (2023-12-01) -
PD-1 and beyond to Activate T Cells in Cutaneous Squamous Cell Cancers: The Case for 4-1BB and VISTA Antibodies in Combination Therapy
by: Quentin Wright, et al.
Published: (2021-07-01) -
Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications
by: Shahram Salek-Ardakani, et al.
Published: (2023-08-01) -
A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity
by: Lian-sheng Cheng, et al.
Published: (2022-09-01) -
OCULAR INJURIES CAUSED BY BB GUN
by: M.S. Farahvash
Published: (1999-08-01)